{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:52:01Z","timestamp":1777420321545,"version":"3.51.4"},"reference-count":42,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the therapeutic profile of elranatamab, a novel bispecific T-cell-redirecting therapy, in treating relapsed or refractory (R\/R) multiple myeloma (MM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>\n                      A PubMed search was conducted for English-language articles published from January 2000 through June 2024, using the search terms:\n                      <jats:italic>PF-06863135, elranatamab, Elrexfio<\/jats:italic>\n                      , and \u201c\n                      <jats:italic>Multiple Myeloma.<\/jats:italic>\n                      \u201d Additional data were obtained from ClinicalTrials.gov and other pertinent publications and meeting abstracts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>Clinical trials, guidelines, and prescribing information pertaining to elranatamab were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>The phase II MagentisMM-3 trial demonstrated an overall response rate of 61.0% (95% confidence interval, 51.8-69.6) in patients na\u00efve to B-cell maturation antigen targeting therapy (cohort A, n = 123), establishing elranatamab monotherapy as a viable treatment option for patients with R\/R MM who have received at least 4 prior lines of therapy. The duration of response and progression-free survival at 12 months were 75.3% and 56.6%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison with existing drugs:<\/jats:title>\n                    <jats:p>Despite the promising activity of elranatamab in R\/R MM, the significant treatment-related adverse effects (AEs) associated with this therapy necessitate careful monitoring and expert management. Common AEs include cytokine release syndrome, neurotoxicity, hematologic toxicity, and infectious complications. The cost-effectiveness of elranatamab has yet to be evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Elranatamab is approved by the Food and Drug Administration as a treatment option for patients with heavily pretreated R\/R MM. Further studies are warranted to identify the optimal treatment strategy for elranatamab and other bispecific antibodies in the management of R\/R MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241281742","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T14:14:04Z","timestamp":1729174444000},"page":"473-484","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Engaging a New Treatment Paradigm: Elranatamab in Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8163-2117","authenticated-orcid":false,"given":"George","family":"Saied","sequence":"first","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-0398","authenticated-orcid":false,"given":"Zachery","family":"Halford","sequence":"additional","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_2_4_2","unstructured":"National Comprehensive Cancer Network. Multiple myeloma (version 4.2024). Date unknown. Accessed July 24 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_2_7_2","unstructured":"Abecma (idecabtagene vicleucel) [prescribing information]. Celgene Corporation; 2024."},{"key":"e_1_3_2_8_2","unstructured":"Carvykti (ciltacabtagene autoleucel) [prescribing information]. Janssen Biotech Inc; 2024."},{"key":"e_1_3_2_9_2","unstructured":"Tecvayli (teclistamab-cqyv) [prescribing information]. Janssen Biotech Inc; 2024."},{"key":"e_1_3_2_10_2","unstructured":"Elrexfio (elranatamab-bcmm) [prescribing information]. Pfizer Inc; 2023."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S151282"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00521-4"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/20363613231207483"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2022.138"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020179"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_2_20_2","volume-title":"Paper presented at the European Hematology Association;","author":"Mohty M","year":"2024","unstructured":"Mohty M, Iida S, Bahlis NJ, et al Long-term survival after elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM): MagetisMM-3 [abstract]. Paper presented at the European Hematology Association; June 2024; Madrid, Spain."},{"key":"e_1_3_2_21_2","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. Accessed June 10 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000952"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin Y","year":"2023","unstructured":"Lin Y, Martin TG, Usmani SZ, et al CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41(suppl 16):8009.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8011"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967676.59550.94"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2313628"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174270"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/blood-2023-187086","article-title":"Tocilizumab prophylaxis for patients treated with teclistamab: a single-center experience","volume":"142","author":"Kowalski A","year":"2023","unstructured":"Kowalski A, Lykon JL, Diamond B, et al Tocilizumab prophylaxis for patients treated with teclistamab: a single-center experience. Blood. 2023;142(suppl 1):4709.","journal-title":"Blood"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18909"},{"key":"e_1_3_2_38_2","unstructured":"Merative.Micromedex RED BOOK: Drug Pricing.Accessed June 10 2024.https:\/\/www.merative.com"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2021.04.005"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.008"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050"},{"key":"e_1_3_2_43_2","unstructured":"MagnetisMM-5: study of elranatamab (PF-06863135) monotherapy and elranatamab + daratumumab versus daratumumab + pomalidomide + dexamethasone in participants with relapsed\/refractory multiple myeloma (MAGNETISMM-5). Accessed July 24 2024. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05020236"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241281742","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241281742","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241281742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:51Z","timestamp":1777374831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241281742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/10600280241281742"],"URL":"https:\/\/doi.org\/10.1177\/10600280241281742","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]}}}